Ellen V. Sigal

Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement

Edward S. Kim, Suanna S. Bruinooge, Samantha Roberts et al. · Journal of Clinical Oncology · 2017 · 448 citations

Eligibility Criteria, Clinical Endpoint, American Society +16

Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400

Roy S. Herbst, David R. Gandara, Fred R. Hirsch et al. · Clinical Cancer Research · 2015 · 232 citations · Full text

Engineering, Biomarker-driven Protocol, Advanced Lung Disease +16

Breaking a Vicious Cycle

Daniel F. Hayes, Jeff Allen, Carolyn C. Compton et al. · Science Translational Medicine · 2013 · 121 citations

Tumor Biology Research, Cancer Management, Pathology +17

Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol

Mary W. Redman, Vassiliki A. Papadimitrakopoulou, Katherine Minichiello et al. · The Lancet Oncology · 2020 · 114 citations · Full text

Prognostic Biomarkers, Medicine, Biomarker Target +10

Despite Criticism Of The FDA Review Process, New Cancer Drugs Reach Patients Sooner In The United States Than In Europe

Samantha Roberts, Jeff Allen, Ellen V. Sigal · Health Affairs · 2011 · 67 citations

Cancer Management, Pharmacotherapy, Us Food +16